Price (GBX)
151.50 -%
DXRXORD GBP0.002
Track
Open / Last close
- / 151.50
High / Low
151.50 / 149.00
Bid / Offer
145.00 / 158.00
Turnover
Special Condition: -
Trading Status: Market Close
As at 04.07.20 04:01:00 - All data delayed at least 15 minutes

Diaceutics PLC instruments

Select instrument to view
Equity (1)
Code Instrument name Price Change Type Documentation
DXRXORD GBP0.002151.50
GBX
-Equity-

Price information

What's this?
Open price
-
Previous close price / date
151.50 / 03 July 2020
Volume
6,842
Turnover
-
52 week range
84.50 / 162.50
YTD return
48.53
1 year return
79.29

Instrument information

What's this?
Instrument market cap (£m)
127.36
Earnings per share
-
Dividend (yield)
- %
Issue date
21 March 2019
ISIN
GB00BJQTGV64
SEDOL
BJQTGV6
Market identifier code (MIC)
AIMX
Country of share register
GB
Market segment
ASQ1
Trading service
SETSqx
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
03.07.20 12:22:45 148.50 GBX 769 1,141.97 Off-Book - AIMX
03.07.20 12:16:13 157.00 GBX 1,000 1,570.00 Off-Book - AIMX
03.07.20 10:38:09 150.00 GBX 4,922 7,383.00 Off-Book - AIMX
03.07.20 10:14:12 157.00 GBX 151 237.07 Off-Book - AIMX
02.07.20 16:28:45 150.00 GBX 1,740 2,610.00 Off-Book N AIMX

Equity Research

from Diaceutics PLC
Cenkos: Diaceutics Plc -- Launching the DXRX Diagnostics Network

Diaceutics is launching a cloud based diagnostics commercialisation platform for the precision medicine market that will bring significant functional gains to customers and create meaningful internal efficiencies. The company has raised £20.5m gross in an equity Placing of new ordinary shares to fun ...

View report
Small Cap Feast

View report
SP Angel Healthcare Conditions

Novacyt (NCYT.L): First orders from Public Health England | Diaceutics (DXRX.L): Financial results for 2019 | Tekcapital (TEK.L): Belluscura files a new patent application

View report
Cenkos: Diaceutics Plc - Recession proof growth

The 30% growth in revenues generated last year only partially reflects the deployment of the IPO proceeds in data and expansionary activities. We conservatively forecast c20% organic growth going forward but see an addressable market enlarging at a much faster rate. Diaceutics offers a recession pro ...

View report
Cenkos: Diaceutics Plc -- Beat and raise

Revenue, earnings and cash are all ahead of forecast. 2019E was an excellent year for the business and the IPO proceeds are only just beginning to positively impact trading. We are upgrading our revenue forecast for 2020E. Nexus is on course for delivery later this year and we see this platform appr ...

View report

Contacts

from Diaceutics PLC
Walbrook PR
Financial PR and IR
atDiaceutics PLC
020 7933 8780
diaceutics@walbrookpr.com
Issuer presentations live and on demand
Watch on Spark Live